Introducing ALiCE®
The ALiCE® technology began its life as a research tool, jointly developed by the Frauenhofer Institute for Molecular Biology and Applied Ecology in collaboration with Corteva Agriscience.
In 2018, LenioBio acquired the exclusive license to further develop and commercialize the technology. Since then, LenioBio has made significant strides, transforming ALiCE® into a commercial research kit for small-scale protein production and offering access to the full power of ALiCE as an protein production service. However, this is just the beginning of our ambitious journey.
The year 2022 marked a pivotal moment for us as we successfully scaled our technology, opening doors to the next phase of ALiCE®’s development.
Today ALiCE is a research tool, providing vital support for drug and vaccine discovery and development. Looking ahead, our R&D roadmap to GMP certification will position ALiCE® as a cornerstone in advancing clinical development and manufacturing. Our ultimate goal: to provide biopharma and vaccine manufacturers with access to our proprietary cell-free expression technology, facilitating all stages of the manufacturing process. From lead identification and pre-clinical analysis to clinical trials and full-scale production, we aim to revolutionize the industry.
OUR MISSION IS CLEAR:
To reduce development times and enable the production of medicines that were once considered unattainable. We believe ALiCE® holds the potential to reshape the future of medicine production and positively impact countless lives.